Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults

Vaccine

Volumn 31, Issue 47, 2013, Pages 5572-5578

  Pépin, Stéphanie ^a   Donazzolo, Yves ^b   Jambrecina, Alen ^c   Salamand, Camille ^a   Saville, Melanie ^a  

^a SANOFI PASTEUR   (France)

^b Eurofins Medinet Inc   (Germany)

^c MediGate GmbH   (Germany)

Author keywords

Immunogenicity; Influenza; Quadrivalent; Safety; Trivalent; Vaccine

Indexed keywords

INFLUENZA VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INJECTION SITE PAIN; INJECTION SITE PRURITUS; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; VACCINATION;

IMMUNOGENICITY; INFLUENZA; QUADRIVALENT; SAFETY; TRIVALENT; VACCINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84886785732     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.069     Document Type: Article

References (19)

1. McCullers J.A., Saito T., Iverson A.R. Multiple genotypes of influenza B virus circulated between 1979 and 2003. J Virol 2004, 78(23):12817-12828.
2. Rota P.A., Wallis T.R., Harmon M.W., Rota J.S., Kendal A.P., Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990, 175(1):59-68.
3. Toback S.L., Rothstein E., Bhatt P., Carr W., Ambrose C.S. In-office influenza vaccination by US pediatric providers varies greatly and is higher among smaller offices. Clin Pediatr (Phila) 2012, 51(6):551-559.
4. McCullers J.A., Hayden F.G. Fatal influenza B infections: time to reexamine influenza research priorities. J Infect Dis 2012, 205(6):870-872.
5. Belshe R.B., Coelingh K., Ambrose C.S., Woo J.C., Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2010, 28(9):2149-2156.
6. Belshe R.B. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010, 28(Suppl. 4):D45-D53.
7. Traynor K. First quadrivalent flu vaccine approved. Am J Health Syst Pharm 2012, 69(7):538.
8. Reed C., Meltzer M.I., Finelli L., Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012, 30(11):1993-1998.
9. Lee B.Y., Bartsch S.M., Willig A.M. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2012, 30(52):7443-7446.
10. Greenberg D.P., Robertson C.A., Noss M.J., Blatter M.M., Biedenbender R., Decker M.D. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 2013, 31(5):770-776.
11. Domachowske J.B., Pankow-Culot H., Bautista M., Feng Y., Claeys C., Peeters M., et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013, 207(12):1878-1887.
12. Goodwin K., Viboud C., Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006, 24(8):1159-1169.
13. McElhaney J.E., Zhou X., Talbot H.K., Soethout E., Bleackley R.C., Granville D.J., et al. The unmet need in the elderly: how immunosenescence. CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine 2012, 30(12):2060-2067.
14. Block S.L., Yi T., Sheldon E., Dubovsky F., Falloon J. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine 2011, 29(50):9391-9397.
15. Block S.L., Falloon J., Hirschfield J.A., Krilov L.R., Dubovsky F., Yi T., et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J 2012, 31(7):745-751.
16. Camilloni B., Neri M., Lepri E., Iorio A.M. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. Vaccine 2009, 27(31):4099-4103.
17. Zuckerman M.A., Wood J., Chakraverty P., Taylor J., Heath A.B., Oxford J.S. Serological responses in volunteers to inactivated trivalent subunit influenza vaccine: antibody reactivity with epidemic influenza A and B strains and evidence of a rapid immune response. J Med Virol 1991, 33(2):133-137.
18. Pyhala R., Kleemola M., Kumpulainen V., Vartiainen E., Lappi S., Ponka A., et al. Immune response to inactivated influenza virus vaccine: antibody reactivity with epidemic influenza B viruses of two highly distinct evolutionary lineages. Vaccine 1992, 10(9):631-636.
19. Baldo V., Baldovin T., Floreani A., Fragapane E., Trivello R., Family Medicine G. Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. J Clin Immunol 2007, 27(5):542-547.